Disease-modifying drugs, multiple sclerosis and infection-related healthcare use in British Columbia, Canada: a population-based study.

Graf J, Ng HS, Zhu F, Zhao Y, Wijnands JM, Evans C, Fisk JD, Marrie RA, Tremlett H.

Open source

DOI
10.1016/j.lana.2023.100667
Published
2024-01-06
Container
Lancet Reg Health Am
Publisher
Not recorded
Open access
yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.lana.2023.100667,
  title = {Disease-modifying drugs, multiple sclerosis and infection-related healthcare use in British Columbia, Canada: a population-based study.},
  author = {Graf J and  Ng HS and  Zhu F and  Zhao Y and  Wijnands JM and  Evans C and  Fisk JD and  Marrie RA and  Tremlett H.},
  year = {2024},
  journal = {Lancet Reg Health Am},
  doi = {10.1016/j.lana.2023.100667},
  url = {https://doi.org/10.1016/j.lana.2023.100667}
}

RIS

TY  - JOUR
TI  - Disease-modifying drugs, multiple sclerosis and infection-related healthcare use in British Columbia, Canada: a population-based study.
AU  - Graf J
AU  -  Ng HS
AU  -  Zhu F
AU  -  Zhao Y
AU  -  Wijnands JM
AU  -  Evans C
AU  -  Fisk JD
AU  -  Marrie RA
AU  -  Tremlett H.
PY  - 2024
JO  - Lancet Reg Health Am
DO  - 10.1016/j.lana.2023.100667
UR  - https://doi.org/10.1016/j.lana.2023.100667
ER  - 

APA

J, G., HS, N., F, Z., Y, Z., JM, W., C, E., JD, F., RA, M., & H., T. (2024). Disease-modifying drugs, multiple sclerosis and infection-related healthcare use in British Columbia, Canada: a population-based study.. Lancet Reg Health Am. https://doi.org/10.1016/j.lana.2023.100667

Source records